S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Expert who called the bottom of the 2020 and 2022 crashes releases new forecast: (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"The Bull Market Is Officially OVER"  (Ad)pixel
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Expert who called the bottom of the 2020 and 2022 crashes releases new forecast: (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"The Bull Market Is Officially OVER"  (Ad)pixel
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Expert who called the bottom of the 2020 and 2022 crashes releases new forecast: (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"The Bull Market Is Officially OVER"  (Ad)pixel
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Expert who called the bottom of the 2020 and 2022 crashes releases new forecast: (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"The Bull Market Is Officially OVER"  (Ad)pixel
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:JSPR

Jasper Therapeutics - JSPR Stock Forecast, Price & News

$0.56
-0.02 (-3.43%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.56
$0.61
50-Day Range
$0.56
$0.89
52-Week Range
$0.56
$10.69
Volume
14,635 shs
Average Volume
62,832 shs
Market Capitalization
$21.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25

Jasper Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,188.4% Upside
$7.25 Price Target
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.34) to ($1.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

548th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

91st out of 171 stocks

JSPR stock logo

About Jasper Therapeutics (NASDAQ:JSPR) Stock

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPR Stock News Headlines

Defy EOY Volatility with Artificial Intelligence
Have you ever heard if you are having issues in your trading, it could be that it's not you - it really is the market? Well, you’re in control. You can sit on the sideline when it feels right, or better yet anticipate massive trend reversals with A.I. You’ve got to see it live to understand it. pixel
Jasper Therapeutics to Present at Upcoming Conferences
Defy EOY Volatility with Artificial Intelligence
Have you ever heard if you are having issues in your trading, it could be that it's not you - it really is the market? Well, you’re in control. You can sit on the sideline when it feels right, or better yet anticipate massive trend reversals with A.I. You’ve got to see it live to understand it. pixel
See More Headlines
Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPR Company Calendar

Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/17/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JSPR
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,188.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-30,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.84 per share

Miscellaneous

Free Float
29,628,000
Market Cap
$21.37 million
Optionable
Not Optionable
Beta
1.00

Key Executives

  • Dr. Judith Anne Shizuru M.D. (Age 65)
    Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
    Comp: $260.77k
  • Mr. Jeetinder Singh Mahal M.B.A. (Age 49)
    CFO, COO & Corp. Sec.
    Comp: $461.12k
  • Dr. Kevin N. Heller M.D. (Age 51)
    Exec. VP of R&D
    Comp: $617.99k
  • Mr. Ronald A. Martell (Age 60)
    Pres, CEO & Director
  • Dr. Susan Prohaska Ph.D.
    Co-Founder and VP of Operations & Program Management
  • Dr. Carol Zoltowski (Age 72)
    Sr. VP of Regulatory Affairs & Quality
  • Dr. Wendy Pang M.D.
    Ph.D., Sr. VP of Research & Translational Medicine













JSPR Stock - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings
or view top-rated stocks.

What is Jasper Therapeutics' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year target prices for Jasper Therapeutics' stock. Their JSPR share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.25 in the next year. This suggests a possible upside of 1,188.4% from the stock's current price.
View analysts price targets for JSPR
or view top-rated stocks among Wall Street analysts.

How have JSPR shares performed in 2022?

Jasper Therapeutics' stock was trading at $7.85 on January 1st, 2022. Since then, JSPR shares have decreased by 92.8% and is now trading at $0.5627.
View the best growth stocks for 2022 here
.

Are investors shorting Jasper Therapeutics?

Jasper Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 110,100 shares, an increase of 37.6% from the October 31st total of 80,000 shares. Based on an average daily trading volume, of 70,300 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.9% of the company's stock are short sold.
View Jasper Therapeutics' Short Interest
.

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 17th 2023.
View our JSPR earnings forecast
.

What is Jasper Therapeutics' stock symbol?

Jasper Therapeutics trades on the NASDAQ under the ticker symbol "JSPR."

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (8.45%), Vanguard Group Inc. (1.45%), Fernwood Investment Management LLC (0.81%), UBS Group AG (0.51%) and Forefront Analytics LLC (0.33%).
View institutional ownership trends
.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jasper Therapeutics' stock price today?

One share of JSPR stock can currently be purchased for approximately $0.56.

How much money does Jasper Therapeutics make?

Jasper Therapeutics (NASDAQ:JSPR) has a market capitalization of $21.37 million.

How can I contact Jasper Therapeutics?

Jasper Therapeutics' mailing address is 1177 AVENUE OF THE AMERICAS FL 40, NEW YORK NY, 10036. The official website for the company is jaspertherapeutics.com. The company can be reached via phone at 650-549-1400 or via email at jmullaly@lifesciadvisors.com.

This page (NASDAQ:JSPR) was last updated on 12/8/2022 by MarketBeat.com Staff